Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: November 2007
-
By Kevin E. Noonan — The following is part of a continuing series on how to address the very real problems facing the U.S. Patent and Trademark Office. A day after the day of rejoicing for inventors, patent practitioners, examiners, and seemingly all of civilization, fair-minded people will concede that the U.S. Patent…
-
By Sherri Oslick — Ranbaxy Laboratories, Astellas Pharma US, Inc., and Boehringer Ingelheim Corporation have announced their agreement to enter into a joint stipulation of dismissal without prejudice in their lawsuit over FLOMAX® (tamsulosin hydrochloride, used to treat benign prostatic hyperplasia). Under the terms of the settlement agreement, Ranbaxy will have the opportunity…
-
By Robert Dailey — AstraZeneca and Israeli generic drug manufacturer Dexcel Pharma recently settled litigation involving the 20 mg delayed-release formulation of omeprazole (Prilosec®). Under the agreement, Dexcel and its partner, Perrigo Company, will have the exclusive marketing rights to the store-branded OTC version of omeprazole. In May 2006, AstraZeneca had filed suit…
-
By Christopher P. Singer — EFS-Web 1.2 Release In an e-Commerce alert notice sent by e-mail on November 8, 2007, the USPTO announced that EFS-Web 1.2 should be released on November 11, 2007. This update to EFS-Web will allow e-filers to: Use the newly available fillable Form SB16 – Provisional Application Cover Sheet;…
-
By Donald Zuhn — The following is part of a continuing series on how to address the very real problems facing the U.S. Patent and Trademark Office. A day after the day of rejoicing for inventors, patent practitioners, examiners, and seemingly all of civilization, fair-minded people will concede that the U.S. Patent and…
-
By Christopher P. Singer — On November 7, 2007, the Industry Trilateral Group, which includes the Intellectual Property Owners Association (IPO), the American Intellectual Property Law Association (AIPLA), Business Europe, the Japan Intellectual Property Association (JIPA), and practitioner groups the European Patent Institute (epi) and the Japan Patent Attorneys Association (JPAA), published a…
-
By Kevin E. Noonan — Responding to outrage, protest, and threats of political and legal action, or perhaps just belatedly recognizing that it was in the middle of a public relations nightmare, Genentech last week announced that it would delay until the end of the year implementation of its decision to "no longer…
-
By Kevin E. Noonan — The following is part of a continuing series on how to address the very real problems facing the U.S. Patent and Trademark Office. A day after the day of rejoicing for inventors, patent practitioners, examiners, and seemingly all of civilization, fair-minded people will concede that the U.S. Patent…
-
By Donald Zuhn — Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the U.S. Patent and Trademark Office Margaret Peterlin (at right) testified today at a House of Representatives hearing on teleworking. The hearing, entitled "Telework: Breaking New Ground?" was held by the Subcommittee on Federal Workforce, Postal Service,…
-
By Kevin E. Noonan — Claude Barfield and John E. Calfee of the American Enterprise Institute opined on the Op-Ed page of The Wall Street Journal last Monday, discussing the wisdom (or lack of it) in patent "reform" bills pending in Congress. While generally consistent with an informed appreciation of the benefits of…
Patent Docs 